Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA

Simple item page
AuthorMalgorzata Pawlowskaen
AuthorKrzysztof Domagalskien
OrcidMalgorzata Pawlowska [0000-0002-6044-0425]en
OrcidKrzysztof Domagalski [0000-0002-9766-8730]en
Issued Date2017-08-31en
AbstractThe exact number of HBV/HCV co-infected patients is unknown. In many cases of HBV/HCV co-infection, HCV inhibits replication of HBV. After treatment and eradication of the dominant virus, the other one may then become active. The overall dominant effect appears to be hepatitis C over hepatitis B. Therefore, when planning treatment for eradication of HCV, the risk of HBV reactivation should be taken into account. In interferon-based therapies of patients with HBV/HCV co-infection, some cases of HBV reactivation without hepatitis were observed because IFN is effective against both viruses. In contrast, DAA treatment of hepatitis C in HBV/HCV co-infection is not well established. Currently, no clinical trials have been published regarding treatment of HBV/HCV co-infected patients with HCV DAA therapy. There is several research on HCV DAA therapy in HBV/HCV co-infection, which describes cases of HBV reactivation during and after DDA therapy for HCV. Result of the first available studies demonstrated that patients with HBV/HCV co-infection treated with DAA against HCV should be monitored for HBV reactivation during and after DAA treatment, even though HBV may be inactive at the time of treatment initiation.en
DOIhttps://doi.org/10.5812/hepatmon.12317en
KeywordHepatitis B Virusen
KeywordHepatitis C Virusen
KeywordHBV/HCV Co-Infectionen
KeywordHBV Reactivationen
KeywordDirect-Acting Antiviralen
PublisherBrieflandsen
TitleRisk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAAen
TypeReview Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
hepatmon-17-08-12317.pdf
Size:
190.94 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Hepatitis Monthly